The scRNA-seq data of CD3+TILs from human lung cancer reveal that the CD8+T-LAYN (PD-1highCTLA-4high) is the predominant subpopulation of CD103high CD8+T cells, and these cells are the major subset in response to anti-PD-1 therapy [34]. This evidence concerns the gene CD8A and lung carcinoma.